Press Releases
Search
-
15 Nov 2012
bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays
Quanterix’s Simoa™ technology to be developed for diagnostic applications. bioMérieux gains exclusive rights for clinical laboratories and industrial applications. bioMérieux takes equity stake in Qua...
-
07 Nov 2012
VIDAS® 3, the New-generation VIDAS®
VIDAS® 3, the New-generation VIDAS® Presented at the JIB International Biologists Congress...
-
31 Oct 2012
Dr. Mark Miller joins bioMérieux as Chief Medical Officer
World-leading expert on infectious disease prevention and control to enhance medical value of bioMérieux’s solutions...
-
23 Oct 2012
bioMérieux - Business Review for the nine months ended September 30, 2012
Sales Up 7.5% at constant exchange rates Of which 3.2%* organic growth Confirmed strong momentum in emerging markets 28% of consolidated sales 17%* organic growth...
-
09 Oct 2012
Avis de projet de fusion bioMérieux / AES Laboratoire groupe
French version only...
-
02 Oct 2012
Thermo Fisher Scientific and bioMérieux Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker
Procalcitonin (PCT) Immunoassay is Sustained on VIDAS® Instruments...
-
21 Sep 2012
Avis de projet de fusion bioMérieux/ARGENE
French version only...
-
04 Sep 2012
bioMérieux - First-Half Results at June 30, 2012
Solid financial performance: €128 million in operating income before non-recurring items, up 6.5% Strong increase in cash flow Faster expansion in emerging markets: India: acquisition of molecular bio...
-
19 Jul 2012
bioMérieux - First-Half 2012 Business Review
Sales Up 8.7% at constant exchange rates Of which 2.9% through organic growth bioMérieux China becomes the Group's 3rd largest company, with sales up 48%* Solid 22%* growth in sales of the Full Microb...
-
03 May 2012
bioMérieux Completes its VIDAS® Hepatitis Panel with a New Test for the Diagnosis of Hepatitis C
Marcy l’Etoile, France, May 3, 2012 — bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of VIDAS® Anti-HCV for the detection of the hepatitis C virus (HCV). With th...
-
24 Apr 2012
bioMérieux - First-Quarter 2012 Business Review
Sales up 9.3% at constant exchange rates Of which 3.1% organic growth, in line with objectives Strong momentum* in China (up 47%) and India (up 31%) Solid performance* in industrial applications (up 1...
-
12 Apr 2012
bioMérieux’s Myla® Named as Finalist in the 2012 Medical Design Excellence Awards
Myla middleware recognized for groundbreaking innovation in In Vitro Diagnostics...
-
27 Mar 2012
Detection of Schmallenberg virus made possible by bioMérieux: the ADIAGENE PCR kit has been validated by ANSES
Marcy l’Etoile, France – ADIAGENE, a member of the bioMérieux group and specialized in diagnostics for animal health, has obtained ANSES validation for a kit for the detection of Schmallenberg virus, ...
-
13 Mar 2012
bioMérieux - 2011 Financial Results
Solid financial performance: Sales at constant exchange rates: up 6.5% Including organic growth: up 4.1% Operating margin before non-recurring items: 18% Confirmed medium and long-term growth potentia...
-
14 Feb 2012
biomerieux-issues-reminder
Marcy l'Etoile - bioMérieux issues a reminder that on January 24, 2012, it set and communicated its objectives for 2012 sales growth. The Company is targeting organic growth between 3-5% or 6-8% at co...